SPPI News and Press, Spectrum Pharmaceuticals Inc. From 04/05/21

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations. The company w...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s any lesson to be learned about the novel coronavirus as it relates to the investment market, it’s that the old guard is on the cusp of change. Prior to the pandemic, one of the biggest debates betwe...

Gainers: Greenlane (GNLN) +37%, SunLink Health Systems (SSY) +17%, Aquestive Therapeutics (AQST) +14%, Evolus (EOLS) +14%, Spectrum Pharmaceuticals (SPPI) +11%.Losers: 9 Meters Biopharma (NMTR) -22%, Delcath Systems (DCTH) -20%, Celsion (CLSN)...

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2020 Results Earnings Conference Call March 30, 2021, 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and CEO Dr. François Lebel - Chief Medical Officer Tom Riga - Chief Operating Officer Conference...

Image source: The Motley Fool. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) Q4 2020 Earnings Call Mar 30, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals Inc (SPPI) Q4 2020 Earnings Call Tran...

Spectrum Pharmaceuticals (SPPI): Q4 Non-GAAP EPS of -$0.20; GAAP EPS of -$0.36 misses by $0.07.Spectrum reported cash, equivalents, and marketable securities of approximately $180.0 million as of December 31, 2020, compared to $224 million at December 31, 2019.Shares +3.92%.Press Release Fo...

Poziotinib receives Fast Track Designation from FDA Preliminary safety and efficacy data for poziotinib twice daily dosing (BID) demonstrates improved anti-tumor activity and reduced toxicity relative to once daily dosing FDA has scheduled the pre-approval inspection a...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March 30, ...

Wall Street is betting on the biotech industry. Many biopharma stocks are close to developing drugs for chronic and life-threatening ailments. With impressive clinical trial results and growth potential, we believe stocks such as Immunovant (IMVT), Zogenix (ZGNX), and Spectrum Pharmaceuticals...

Spectrum Pharmaceuticals ([[SPPI]] -3.0%) has announced that the FDA has scheduled the pre-approval inspection at the ROLONTIS (eflapegrastim) manufacturing site for May 2021.“We believe the pre-approval inspection marks the final step in the ROLONTIS review process,” ...